TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06375577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 45 grams Voom Pocket Rocket Electro Energy
Description: Participants will be required to consume 45 grams (in carbohydrates) of the Voom Pocket Rocket Electro Energy on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 45 grams SIS Go Isotonic Energy Gel
Description: Participants will be required to consume 45 grams (in carbohydrates) SIS Isotonic Energy Gel on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 45 grams Maurten Gel 160
Description: Participants will be required to consume 45 grams (in carbohydrates) Maurten Gel 160 on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
Study: NCT05571969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2X-121 and dovitinib
Description: The dose levels to be evaluated in Part 1 are:~Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose: 400 mg + evening dose: 400 mg); Cohort 3 1000 mg (morning dose: 400 mg + evening dose: 600 mg);~The dose levels to be evaluated in Part 2 are:~Cohort 1 2X-121 (MTD) + 300 mg dovitinib; Cohort 2 2X-121 (MTD) + 400 mg dovitinib; Cohort 3 2X-121 (MTD) + 500 mg dovitinib;
Study: NCT06574386

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessment
Description: Neurodevelopmental assessment
Study: NCT05957159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detoxification Program
Description: Patients will begin inpatient or outpatient detoxification prior to completing imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PKAB
Description: 90 PET Imaging Scan using \[11C\]LY2795050 (AKA \[11C\]PKAB)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PKAB
Description: 90 PET Imaging Scan using \[11C\]LY2795050 (AKA \[11C\]PKAB)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CFN
Description: 90 Pet Imaging Scan using \[11C\]-Carfentanil

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CFN
Description: 90 Pet Imaging Scan using \[11C\]-Carfentanil
Study: NCT04914975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: The stimulation will be conducted at home or at the SPC for half an hour about 30 minutes before the usual bowel emptying time. Four adhesive electrodes are attached to the abdominal wall for the neuromuscular electrical stimulation. The abdominal muscles are stimulated in such a way that activation occurs, i.e. the muscle alternately contracts and relaxes again. The stimulation sessions will be documented with a defined protocol. In addition, the stool consistency is rated according to the Bristol Stool Form Scale.
Study: NCT05650255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Digital Twin for Exoskeleton Pilot
Description: The purpose of this project is to establish a digital twin of this driving, which will perform the driving action in parallel, and calculate in parallel in the virtual environment the torque required to provide each joint torque to maintain stable walking without falling, and this torque can be used as a monitoring basis for the auxiliary torque of each axis for the exoskeleton. When the exoskeleton's movements are out of range of a stable gait, the controller can warn and attenuate the output of auxiliary forces, and on the other hand, it has the opportunity to analyze whether the intention of driving is to switch the movement mode - such as stopping, or sitting, squatting, etc.
Study: NCT06153758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: Danuglipron oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: Danuglipron oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: Danuglipron oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: Danuglipron oral tablets
Study: NCT06262100

Intervention type: DEVICE
Group type: OTHER
Intervention: Carragelose
Description: Application of Carragelose containing eye drops
Study: NCT04789915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Add on treatment with memantine to aripiprazole.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo add on to aripiprazole
Study: NCT05761275

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective cystectomy
Description: Adnexal cyst removal for presumed benign adnexal pathology.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective cystectomy
Description: Adnexal cyst removal for presumed benign adnexal pathology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective oophorectomy
Description: Ovarian removal for presumed benign adnexal pathology.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective oophorectomy
Description: Ovarian removal for presumed benign adnexal pathology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective salpingectomy
Description: Tubal removal for presumed benign adnexal pathology.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective salpingectomy
Description: Tubal removal for presumed benign adnexal pathology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective tubal sterilization
Description: Tubal obstruction as a definitive contraceptive method (tubal cauterization with or without sectioning, partial or total removal of both tubes, or obstruction with small clips/ligatures).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective tubal sterilization
Description: Tubal obstruction as a definitive contraceptive method (tubal cauterization with or without sectioning, partial or total removal of both tubes, or obstruction with small clips/ligatures).
Study: NCT05956769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: thromboelastography
Description: thromboelastography (TEG6)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: thromboelastography
Description: thromboelastography (TEG6)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: thromboelastography
Description: thromboelastography (TEG6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline injection
Study: NCT06079190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4527226
Description: GSK4527226 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4527226
Description: GSK4527226 will be administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT05026177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam
Description: Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 76 weeks at a dose of 50 mg or 100 mg.
Study: NCT05138939

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Red wine A
Description: 8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red wine A
Description: 8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
Study: NCT05026177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam
Description: Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 76 weeks at a dose of 50 mg or 100 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given b.i.d. for 76 weeks
Study: NCT05681845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Participants will receive a single dose of Mim8 subcutaneously in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Participants will receive a single dose of Mim8 subcutaneously in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Participants will receive a single dose of Mim8 subcutaneously in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Participants will receive a single dose of Mim8 subcutaneously in the abdomen.
Study: NCT05601362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gamified Attention Bias Modification
Description: Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gamified Placebo Training
Description: Placebo version of Gamified Attention Bias Modification. (Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias).
Study: NCT05841862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2C-QD
Description: Quantum Dot

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham 2C-QD
Description: Sham Intravitreal Injection
Study: NCT05513807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide treatment
Description: 3g Nicotinamide orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: 3g Placebo orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
Study: NCT05132543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High density micro-electrocorticography for neural speech prothesis
Description: ECoG electrodes are thin, high-density, flexible electrode arrays used for recording electrophysiological signals from the brain.
Study: NCT06260059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Patient will be given 10 mg of Empagliflozin if randomized to the drug arm or will receive placebo drug for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To patients randomized to the placebo group, a placebo pill will be given
Study: NCT05463081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Short Form Health Survey
Description: The Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Short Form Health Survey
Description: The Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal Health Index
Description: Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal Health Index
Description: Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital signs determination
Description: Vital signs determination (respiration rate, blood pressure, pulse rate, body temperature).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital signs determination
Description: Vital signs determination (respiration rate, blood pressure, pulse rate, body temperature).
Study: NCT05101473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: The overall framework will consist of two supervised exercise sessions per week of 30-60 min duration for 12 weeks in order to be able to result in the physiological adaptions that are needed to improve the health of the individual participant.
Study: NCT05463081

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pH of vagina determination
Description: Potential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pH of vagina determination
Description: Potential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical parameters determination
Description: Physical parameters determination (body weight, age, height, body mass index).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical parameters determination
Description: Physical parameters determination (body weight, age, height, body mass index).
Study: NCT06479317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Oral Tablet
Description: Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone oral
Description: Dexamethasone is given at 40mg every morning after meals for 4 consecutive days( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, dexamethasone is given 40mg every day for another consecutive 4 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone oral
Description: Dexamethasone is given at 40mg every morning after meals for 4 consecutive days( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, dexamethasone is given 40mg every day for another consecutive 4 days).
Study: NCT05986708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interview
Description: In addition to routine treatment and care, the patients in the application group were interviewed by the researcher once a week for 6 weeks, within the first hour of HD treatment, for a total of 6 sessions, each session being approximately 30 minutes-1 hour, within the scope of the guided self-determination method.
Study: NCT05190094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)
Description: A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
Study: NCT05138939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red wine A
Description: 8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Red wine B
Description: 8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red wine B
Description: 8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red wine B
Description: 8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
Study: NCT04233606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: Infusion of hypertonic saline to induce an osmotic secretion of the hormone vasopressin
Study: NCT04953130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil® HPV vaccine
Description: Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil® HPV vaccine
Description: Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).
Study: NCT04233606

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Infusion of normal saline to inhibit the secretion of the hormone vasopressin
Study: NCT05138939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
Study: NCT05338190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Rituximab with subcutaneous belimumab
Description: Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combination of Rituximab with subcutaneous placebo
Description: Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
Study: NCT05213585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin cream
Description: Topical application of ivermectin cream to eyelashes of treatment eye.
Study: NCT04701957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
Study: NCT04115501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fraction of Inspired Oxygen
Description: Fraction of Inspired Oxygen during cardiac surgery, including cardiopulmonary bypass
Study: NCT05489016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yuekang Huoxin Pills (concentrated pills)
Description: Huoxin Pill (concentrated pill) is composed of Radix Ginseng, Radix Aconiti Lateralis Preparata, Ganoderma, Flos Carthami, artificial Moschus, cultured calculus bovis in vitro, Fel Ursi, Margarita, Venenum Bufonis, and Borneolum Syntheticum. It has the effect of invigorating qi and promoting blood circulation. It has been marketed in China for more than 30 years. Clinical studies have shown that Huoxin Pill (concentrated pill) has significant clinical efficacy in improving the symptoms and prognosis of coronary heart disease and angina pectoris. Basic studies have also confirmed that Huoxin Pill (concentrated pill) can play a role in myocardial protection by dilating coronary arteries and promoting angiogenesis. It produced by Guangzhou yuekang biopharmaceuticals co., ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yuekang Huoxin Pills (concentrated pills)simulant
Description: Huoxin Pill (concentrated pill) simulant, a placebo-like simulation have no therapeutic effect. The shape, packaging and taste are the same as Huoxin Pill (concentrated pill), produced by Guangzhou yuekang biopharmaceuticals co., ltd.
Study: NCT04780126

Intervention type: OTHER
Intervention: Sarcopenia diagnosis
Description: History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
Study: NCT06348160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iHERO Toolkit Resource
Description: iHERO Toolkit consists of micro-videos and supplemental online resources. Participants will have access to the toolkit housed on pathfactory for 30 days.
Study: NCT06559072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: On the basis of routine treatment for aneurysmal subarachnoid hemorrhage, atorvastatin was administered at an ultra early stage at a dose of 40mg/d for 14 consecutive days
Study: NCT06561412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Produce Prescription
Description: Participants will receive either $40 (families of 2 members or less) or $60 (families of more than 2 members) produce vouchers every 2 weeks for 6 months, for a total of $480 or $720. These vouchers are sponsored by The Food Trust.